Cantitate/Preț
Produs
Total produse
Vezi coșul
Drug Development for Rare Diseases de Bo Yang

Drug Development for Rare Diseases: Chapman & Hall/CRC Biostatistics Series

Editat de Bo Yang, Yang Song, Yijie Zhou
en Limba Engleză Hardback – 13 feb 2023
A disease is defined as rare if the prevalence is fewer than 200,000 in the United States. It is estimated that there are more than 7,000 rare diseases, which collectively affect 30 million Americans. This diverse and complex disease area poses challenges for patients, caregivers, regulators, drug developers and other stakeholders.
Citește tot Restrânge

Din seria Chapman & Hall/CRC Biostatistics Series

  • 9% Controlled Epidemiological Studies
    Preț: 80131 lei
  • 9% Statistical Methods for Dynamic Disease Screening and Spatio-Temporal Disease Surveillance
    Preț: 64331 lei
  • 9% Bayesian Precision Medicine
    Preț: 64304 lei
  • Joint Models for Longitudinal and Time-to-Event Data: With Applications in R
    Preț: 34142 lei
  • Bayesian Analysis with R for Drug Development: Concepts, Algorithms, and Case Studies
    Preț: 31141 lei
  • 8% Statistical Thinking in Clinical Trials
    Preț: 37664 lei
  • Bayesian Adaptive Methods for Clinical Trials
    Preț: 35065 lei
  • 5% Biostatistics for Bioassay
    Preț: 65678 lei
  • Applied Meta-Analysis with R and Stata
    Preț: 35663 lei
  • Real-World Evidence in a Patient-Centric Digital Era
    Preț: 34837 lei
  • Sample Size Calculations in Clinical Research
    Preț: 31141 lei
  • 9% Estimands, Estimators and Sensitivity Analysis in Clinical Trials
    Preț: 72920 lei
  • Interface between Regulation and Statistics in Drug Development
    Preț: 35448 lei
  • Confidence Intervals for Discrete Data in Clinical Research
    Preț: 35903 lei
  • Structural Equation Modeling for Health and Medicine
    Preț: 34289 lei
  • Real-World Evidence in Drug Development and Evaluation
    Preț: 35477 lei
  • Medical Risk Prediction Models: With Ties to Machine Learning
    Preț: 38662 lei
  • 9% Causal Inference in Pharmaceutical Statistics
    Preț: 64152 lei
  • 5% Hybrid Frequentist/Bayesian Power and Bayesian Power in Planning Clinical Trials
    Preț: 33101 lei
  • Cure Models: Methods, Applications, and Implementation
    Preț: 28880 lei
  • 5% Statistical Methods in Health Disparity Research
    Preț: 66954 lei
  • Bayesian Methods in Pharmaceutical Research
    Preț: 36200 lei
  • 9% Value of Information for Healthcare Decision-Making
    Preț: 73199 lei
  • 9% ROC Analysis for Classification and Prediction in Practice
    Preț: 64457 lei
  • Signal Detection for Medical Scientists: Likelihood Ratio Test-based Methodology
    Preț: 35663 lei
  • 9% Innovative Methods for Rare Disease Drug Development
    Preț: 83328 lei
  • 9% Quantitative Methods for Precision Medicine: Pharmacogenomics in Action
    Preț: 60832 lei
  • Single-Arm Phase II Survival Trial Design
    Preț: 35722 lei
  • 9% Statistical Design, Monitoring, and Analysis of Clinical Trials: Principles and Methods
    Preț: 59430 lei
  • 9% Analysis of Incidence Rates
    Preț: 94038 lei
  • 18% Design and Analysis of Clinical Trials for Predictive Medicine
    Preț: 77781 lei
  • 18% Bayesian Methods in Health Economics
    Preț: 69467 lei
  • 18% Medical Biostatistics
    Preț: 170105 lei
  • 26% Dose Finding by the Continual Reassessment Method
    Preț: 87513 lei
  • 18% Design and Analysis of Bridging Studies
    Preț: 77237 lei
  • 25% Statistics In the Pharmaceutical Industry
    Preț: 82563 lei
  • 15% Fundamental Concepts for New Clinical Trialists
    Preț: 66672 lei
  • 25% Statistical Methods for Drug Safety
    Preț: 55758 lei
  • 25% Randomization, Masking, and Allocation Concealment
    Preț: 62583 lei
  • 18% Quantitative Methods for HIV/AIDS Research
    Preț: 77312 lei
  • 25% Design and Analysis of Bioavailability and Bioequivalence Studies
    Preț: 77807 lei
  • 25% Exposure-Response Modeling: Methods and Practical Implementation
    Preț: 62829 lei
  • 18% Modern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects
    Preț: 110598 lei
  • 25% Handbook of Regression and Modeling: Applications for the Clinical and Pharmaceutical Industries
    Preț: 88755 lei
  • 25% Randomized Phase II Cancer Clinical Trials
    Preț: 52681 lei

Preț: 88097 lei

Preț vechi: 107435 lei
-18% Nou

Puncte Express: 1321
Preț estimativ în valută:
16860€ • 17564$ • 14018£

Carte tipărită la comandă

Livrare economică 10-24 februarie 25

 Adaugă în coș

Wish list
Gift list
Am citit!
Adaugă în listă
Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9780367518349
ISBN-10: 0367518341
Pagini: 232
Ilustrații: 1 Tables, color; 22 Tables, black and white; 5 Line drawings, color; 2 Line drawings, black and white; 5 Illustrations, color; 2 Illustrations, black and white
Dimensiuni: 156 x 234 x 14 mm
Greutate: 0.59 kg
Ediția:1
Editura: CRC Press
Colecția Chapman and Hall/CRC
Seria Chapman & Hall/CRC Biostatistics Series

Notă biografică

Bo Yang is the Vice President, Biometrics and Real World Evidence at Vertex Pharmaceuticals, USA.
Yang Song is the Executive Director, Biostatistics Group Head of Pipeline Development at Vertex Pharmaceuticals, USA.
Yijie Zhou is the Executive Director, Real World Statistics and Analytics at Vertex Pharmaceuticals, USA.

Cuprins

1. Introduction to Rare Disease Therapy Development 2. Challenges and Opportunities in Rare Disease Drug 3. Developing Drugs for Rare Diseases: Regulatory Strategies 4. Clinical Trial Design and Analysis Considerations for Rare Diseases 5. Use of Real-World Evidence to Support Drug Development 6. Clinical Development of Pediatric Program within Rare Diseases 7. Use of Modeling and Simulation in Support of Drug Development for Rare Diseases 8. Case Studies of Rare Disease Drug Development

Descriere

A disease is defined as rare if the prevalence is fewer than 200,000 in the United States. It is estimated that there are more than 7,000 rare diseases, which collectively affect 30 million Americans or 10% of the US population.

This diverse and complex disease area poses challenges for patients, caregivers, regulators, drug developers, and other stakeholders.

This book is proposed to give an overview of the common issues facing rare disease drug developers, summarize challenges specific to clinical development in small populations, discuss drug development strategies in the evolving regulatory environment, explain generation and utilization of different data and evidence

inside and beyond clinical trials, and use recent examples to demonstrate these challenges and the development strategies that respond to the challenges.

Key Features:

• Rare disease.

• Drug development.

• Innovative clinical trial design.

• Regulatory approval.

• Real-world evidence.